Un-Audited Financial Results (UFR) for the first quarter ended June 30, 2025, along with the Statutory Auditors' Limited Review Report pursuant to Regulation 33 of the Securities and Exchange ....
Awaiting price reaction for this filing.
Kashyap Tele-Medicines Limited announced its unaudited financial results for the quarter ended June 30, 2025, approved at a board meeting held on August 14, 2025. Revenue from operations stood at just ₹3.90 lakhs, a sharp drop of about 80% from ₹19.20 lakhs in the same quarter last year. The company slipped back into a loss, posting a Loss Before Tax of ₹2.98 lakhs versus a small profit of ₹0.34 lakhs in Q1 FY25, with a Loss After Tax of ₹2.98 lakhs and a basic/diluted EPS of ₹(0.006). Total expenses were ₹2.98 lakhs, leaving no operating cushion. Other equity remained deeply negative at ₹(413.27) lakhs, indicating accumulated losses far exceeding the share capital base of ₹477.22 lakhs.
Shareholders should note the steep revenue collapse and return to losses, combined with persistently negative reserves, which signal serious business weakness. The clean limited review report from Ravi Karia & Associates offers some comfort on reporting quality, but the underlying financials point to heightened going-concern risk that investors should watch closely.